Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Actinium PharmaceuticalsATNM -0.89%17 Debt-to-Equity is 0.04 as of Jun. 2026, which is at its 10-year median of 0.04. GuruFocus rates ATNM with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 958 Biotechnology companies, Actinium Pharmaceuticals ranks better than 75.16% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Actinium Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
ATNM'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.66
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of Actinium Pharmaceuticals was 0.66. The lowest was 0.00. And the median was 0.04.
ATNM's Debt-to-Equity is ranked better than 75.16% of 958
companies
in the Biotechnology industry
Industry Median: 0.16
vs ATNM: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Actinium Pharmaceuticals Debt-to-Equity Related Terms
Actinium Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATNM vs PSTV, IGC, PVCT: Debt-to-Equity Comparison
For the Biotechnology subindustry, Actinium Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actinium Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Actinium Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actinium Pharmaceuticals (ATNM) has a Debt-to-Equity of 0.04 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Actinium Pharmaceuticals and its competitors. This is near median its historical median of 0.04. According to the industry distribution chart, Actinium Pharmaceuticals ranks #238 out of 958 companies in the Biotechnology industry, placing it in the top 24.8%.
Is Actinium Pharmaceuticals' Debt-to-Equity too high?
Actinium Pharmaceuticals' current Debt-to-Equity of 0.04 is near median its 10-year median of 0.04. The Biotechnology industry median Debt-to-Equity is 0.16. Actinium Pharmaceuticals' value of 0.04 is 75% below this industry median. Based on the distribution chart, Actinium Pharmaceuticals ranks #238 out of 958 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Actinium Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Actinium Pharmaceuticals' Debt-to-Equity compare to PSTV and IGC?
According to the Biotechnology industry distribution chart, Actinium Pharmaceuticals ranks #238 out of 958 companies for Debt-to-Equity. This places Actinium Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Actinium Pharmaceuticals' value of 0.04 is 75% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.16, Actinium Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actinium Pharmaceuticals's current Debt-to-Equity of 0.04 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Actinium Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actinium Pharmaceuticals's current Debt-to-Equity is 0.04, which is near median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinium Pharmaceuticals stock overvalued right now?
Actinium Pharmaceuticals (ATNM) has a current Debt-to-Equity of 0.04. The current Debt-to-Equity is 0.04, which is near median its 10-year median of 0.04 and 75% below the Biotechnology industry median of 0.16. Actinium Pharmaceuticals' overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Actinium Pharmaceuticals (ATNM), the current Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
17GF Score
Get the complete analysis for ATNM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATNM has been successfully added to your 
